Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

This initiative will result in an investment of over Eur2 billion into the drug development process in Europe.   IMI is a unique design which will bring together stakeholders from all sectors such as academia, hospitals, public authorities, patient organisations, SMEs and the large biopharmaceutical industries.

The objective of IMI is to support faster discovery, and the development of better medicine for patients and to enhance Europe’s competitiveness in the biopharmaceutical sector.   

8th Call for Proposals:

IMI launched its 8th Call for proposals on 17 December 2012:

Topics included under the IMI programme 'Combating Antibiotic Resistance: New Drugs for Bad Bugs (ND4BB)' *

  • Topic 1C: Innovative Trial Design & Clinical Development (work package 6 of Topic 1)
  • Topic 3: Discovery and development of new drugs combating Gram – negative infections

ND4BB (‘New Drugs for Bad Bugs’) represents a core element of the Action plan against the rising threats from Antimicrobial Resistance adopted by the European Commission as an answer to the Council Conclusions and the European Parliament resolution to establish an EU-wide plan to combat antimicrobial resistance. The ND4BB programme started in IMI’s 6th Call launched in May 2012 with two topics, and further topics are under consideration.

Topics included under the Theme 'Developing an aetiology-based taxonomy for human diseases'

  • Topic A: Approaches to develop a new classification for Systemic Lupus Erythematosus (SLE) and related connective tissue disorders and Rheumatoid Arthritis (RA)
  • Topic B: Approaches to develop a new classification for neurodegenerative disorders with a focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD)

European induced pluripotent stem cell bank

For more detailed information on the 8th Call, including the call text, details on how to participate and all guidance documents click here

Previous IMI calls summary

Previous Calls Summary:
  • Call 1: A total of 15 projects involving 365 teams from around Europe, 24 of which are SME's with a total budget of €281m. Average project size for Call 1 is €18.7m.
  • Call 2: Eight projects involvng 193 teams, 23 of which are SME's working to a combined budget of €172m. Average project budget for Call 2 is €21.5m.
  • Call 3: Evaluations are currently being completed with all applicants expected to know the outcome by end of March 2011. In total there were 7 topics open for proposals in Call 3, with strong Irish participation in at least two of the calls. A total of 32 expressions of interest were received involving 433 applicants with an average number of 13 applicants in the first stage consortia.

National Contact Point(s)

Logo: Enterprise Ireland
Dr Ciaran Duffy
Organisation: Enterprise Ireland
Telephone: +353 (0)1 7272760
Email: Ciaran.Duffy@enterprise-ireland.com
Logo: Health Research Board
Kay Duggan-Walls
Organisation: Health Research Board
Telephone: +353 (0)1 2345187
Email: KDugganWalls@hrb.ie

Leading Ireland's
Participation In FP7

Enterprise Ireland